DUPIXENT MyWay is available to help provide nursing, coverage, and access support. You and your patients can contact DUPIXENT MyWay at 1-844-DUPIXENT (1-844-387-4936).
With the current global pandemic, Sanofi and Regeneron Pharmaceuticals, Inc. would like to reinforce our commitment to you and your patients. As COVID-19 remains a serious concern, we are continuing to closely monitor the latest guidelines from the Centers for Disease Control and Prevention (CDC) to ensure that we have the most up-to-date health and safety guidance in place.
We understand that your patients may contact you with more questions than usual regarding their treatment. We would like to take this opportunity to remind you of important information regarding DUPIXENT and resources available to you and your patients.
aThe mechanism of action of dupilumab in asthma has not been definitively established
For more information about financial assistance options that may be available to help your patients, contact DUPIXENT MyWay at 1-844-DUPIXENT (1-844-387-4936)
Patients and caregivers have access to supplemental injection training without leaving home through the DUPIXENT MyWay support program. There are 2 options available:
In children 12 years of age and older, it is recommended that DUPIXENT be administered by or under supervision of an adult. In children younger than 12 years of age, DUPIXENT should be given by a caregiver.
Additional injection training resources are also available online at DUPIXENT.COM:
DUPIXENT MyWay is available to help provide nursing, coverage, and access support. You and your patients can contact DUPIXENT MyWay at 1-844-DUPIXENT (1-844-387-4936).
CoverMyMeds provides additional prior authorization process related support for DUPIXENT.
Live support is available at
Please refer to the websites of:
We will continue to closely monitor the situation, which has affected so many across the globe, and to evaluate our current support offerings. We hope that you and your loved ones remain safe and healthy.